MX2018010824A - Proteinas de union inducibles y metodos de uso. - Google Patents

Proteinas de union inducibles y metodos de uso.

Info

Publication number
MX2018010824A
MX2018010824A MX2018010824A MX2018010824A MX2018010824A MX 2018010824 A MX2018010824 A MX 2018010824A MX 2018010824 A MX2018010824 A MX 2018010824A MX 2018010824 A MX2018010824 A MX 2018010824A MX 2018010824 A MX2018010824 A MX 2018010824A
Authority
MX
Mexico
Prior art keywords
methods
polypeptide constructs
binding proteins
disclosed
inducible binding
Prior art date
Application number
MX2018010824A
Other languages
English (en)
Inventor
B Dubridge Robert
Evnin Luke
Guenot Jeanmarie
Baeuerle Patrick
Wesche Holger
Panchal Anand
Vinogradova Maia
Original Assignee
Maverick Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverick Therapeutics Inc filed Critical Maverick Therapeutics Inc
Publication of MX2018010824A publication Critical patent/MX2018010824A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente invención se refiere a constructor de polipéptido condicionalmente activados que comprenden un dominio de unión a CD3 activado por proteasa, al menos un dominio de extensión de vida útil, y dos o más dominios de unión a uno o más antígenos de objetivo. También se proporcionan composiciones farmacéuticas de los mismos, así como también ácidos nucleicos, vectores de expresión recombinantes y células hospederas para elaborar tales constructos de polipéptido. También se describen métodos para usar los constructos de polipéptido descritos en la prevención, y/o tratamiento de enfermedades, condiciones y trastornos.
MX2018010824A 2016-03-08 2017-03-08 Proteinas de union inducibles y metodos de uso. MX2018010824A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662305092P 2016-03-08 2016-03-08
PCT/US2017/021435 WO2017156178A1 (en) 2016-03-08 2017-03-08 Inducible binding proteins and methods of use

Publications (1)

Publication Number Publication Date
MX2018010824A true MX2018010824A (es) 2019-05-15

Family

ID=59789722

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010824A MX2018010824A (es) 2016-03-08 2017-03-08 Proteinas de union inducibles y metodos de uso.

Country Status (14)

Country Link
US (1) US20180134789A1 (es)
EP (1) EP3426689A4 (es)
JP (3) JP7195927B2 (es)
KR (2) KR20230041739A (es)
CN (1) CN109071667A (es)
AU (1) AU2017229687A1 (es)
BR (1) BR112018068189A2 (es)
CA (1) CA3016165A1 (es)
IL (1) IL261432B2 (es)
MA (1) MA43816A (es)
MX (1) MX2018010824A (es)
SG (1) SG11201807548SA (es)
TW (2) TW201808990A (es)
WO (1) WO2017156178A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187594A1 (en) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
JP7073258B2 (ja) 2015-11-19 2022-05-23 レビトープ リミテッド 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EA201892693A1 (ru) 2016-05-20 2019-04-30 Харпун Терапьютикс, Инк. Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
KR20190087539A (ko) 2016-11-23 2019-07-24 하푼 테라퓨틱스, 인크. Psma 표적화 삼중특이성 단백질 및 사용 방법
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
WO2018160671A1 (en) * 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Targeted checkpoint inhibitors and methods of use
WO2018204717A1 (en) * 2017-05-03 2018-11-08 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
JP7209936B2 (ja) 2017-05-12 2023-01-23 ハープーン セラピューティクス，インク． Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2019051122A2 (en) 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS
AU2018328291B2 (en) 2017-09-08 2022-10-27 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
US11136403B2 (en) 2017-10-13 2021-10-05 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
CA3078799A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
KR102578682B1 (ko) * 2017-11-01 2023-09-13 난트바이오 인코포레이티드 Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells)
CN110218253B (zh) * 2018-03-02 2020-12-04 广西医科大学 抗CD3的纳米抗体CD3/Nb14及其制备方法与应用
CN110218256B (zh) * 2018-03-02 2020-12-08 广西医科大学 抗CD3的纳米抗体CD3/Nb29及其制备方法与应用
US20210269530A1 (en) * 2018-05-14 2021-09-02 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
KR20210021467A (ko) 2018-05-14 2021-02-26 웨어울프 세라퓨틱스, 인크. 활성화가능한 인터루킨-2 폴리펩타이드 및 이의 사용 방법
BR112020023118A2 (pt) 2018-05-14 2021-04-13 Werewolf Therapeutics, Inc. Polipeptídeos de interleucina 12 ativáveis e métodos de uso destes
US20210292421A1 (en) * 2018-05-14 2021-09-23 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
CN112654633A (zh) * 2018-06-22 2021-04-13 科优基因公司 基于细胞因子的可生物活化药物及其使用方法
US20210309756A1 (en) 2018-08-09 2021-10-07 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
CN113286817A (zh) 2018-09-25 2021-08-20 哈普恩治疗公司 Dll3结合蛋白及使用方法
JP2022523708A (ja) * 2019-01-29 2022-04-26 グリットストーン バイオ インコーポレイテッド 多重特異性結合タンパク質
CA3132651A1 (en) * 2019-03-05 2020-09-10 Takeda Pharmaceutical Limited Company Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens
EP3934762A1 (en) * 2019-03-05 2022-01-12 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CA3137512A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
WO2021097060A1 (en) * 2019-11-13 2021-05-20 Harpoon Therapeutics, Inc. Pro immune modulating molecule comprising a clustering moiety
US20230075633A1 (en) * 2019-12-20 2023-03-09 Shandong Boan Biotechnology Co., Ltd. Optimized anti-cd3 arm in the generation of t-cell bispecific antibodies for immunotherapy
EP4090686A4 (en) * 2020-01-17 2024-03-27 Immune Targeting Inc PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
BR112022019841A2 (pt) 2020-04-09 2022-12-06 Cytomx Therapeutics Inc Composições contendo anticorpos ativáveis
WO2022006562A1 (en) 2020-07-03 2022-01-06 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
KR20230048146A (ko) 2020-08-17 2023-04-10 다케다 야쿠힌 고교 가부시키가이샤 제약된, 조건부 활성화 결합 단백질들
EP4199948A1 (en) * 2020-08-18 2023-06-28 Onchilles Pharma, Inc. Modified serine protease proproteins
WO2022109611A1 (en) 2020-11-20 2022-05-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
CA3201588A1 (en) 2020-12-09 2022-06-16 David Campbell Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
CA3214342A1 (en) 2021-04-06 2022-10-13 Chad May Therapeutic methods using constrained conditionally activated binding proteins
EP4334354A1 (en) 2021-05-06 2024-03-13 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
WO2023034288A1 (en) 2021-08-31 2023-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of autoimmune disorders and cancer
WO2023097024A1 (en) 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005141512A (ru) * 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
BRPI0415457A (pt) * 2003-10-16 2006-12-05 Micromet Ag constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
CA2807269A1 (en) * 2010-08-24 2012-03-01 Roche Glycart Ag Activatable bispecific antibodies
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
SG195072A1 (en) * 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
AR087020A1 (es) * 2011-07-01 2014-02-05 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos
PE20141859A1 (es) * 2012-02-27 2014-12-17 Boehringer Ingelheim Int Polipeptidos de union a cx3cr1
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
JP6407726B2 (ja) * 2012-03-01 2018-10-24 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 長寿命ポリペプチド結合分子
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
KR102301464B1 (ko) * 2013-06-10 2021-09-14 다나-파버 캔서 인스티튜트 인크. 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
RS59907B1 (sr) * 2014-03-28 2020-03-31 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
JP7073258B2 (ja) * 2015-11-19 2022-05-23 レビトープ リミテッド 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完
US20210309756A1 (en) * 2018-08-09 2021-10-07 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins

Also Published As

Publication number Publication date
TW202302631A (zh) 2023-01-16
WO2017156178A1 (en) 2017-09-14
CA3016165A1 (en) 2017-09-14
CN109071667A (zh) 2018-12-21
JP2023123519A (ja) 2023-09-05
JP2019513014A (ja) 2019-05-23
KR20180120245A (ko) 2018-11-05
KR20230041739A (ko) 2023-03-24
EP3426689A4 (en) 2020-01-15
BR112018068189A2 (pt) 2019-02-05
SG11201807548SA (en) 2018-09-27
IL261432A (en) 2018-10-31
KR102501921B1 (ko) 2023-02-21
AU2017229687A1 (en) 2018-09-20
US20180134789A1 (en) 2018-05-17
RU2018134949A3 (es) 2020-08-14
JP7195927B2 (ja) 2022-12-26
MA43816A (fr) 2018-11-28
IL261432B2 (en) 2024-03-01
JP2022140856A (ja) 2022-09-28
EP3426689A1 (en) 2019-01-16
IL261432B1 (en) 2023-11-01
TW201808990A (zh) 2018-03-16
RU2018134949A (ru) 2020-04-08
JP7293456B2 (ja) 2023-06-19

Similar Documents

Publication Publication Date Title
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
ZA202002094B (en) Trispecific proteins and methods of use
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
MX2020004578A (es) Composiciones de casz y metodos de uso.
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12019500596A1 (en) Recombinant binding proteins and their use
WO2019002444A9 (en) NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
MY192481A (en) Factor viii chimeric proteins and uses thereof
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
MX2022004042A (es) Proteinas de union multiespecificas para tratamiento contra el cancer.
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
NZ724196A (en) Uti fusion proteins
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
MX2019014397A (es) Polipeptidos que enlazan adamts5, mmp13 y agrecano.
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.
MX2020009507A (es) Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos.